70 related articles for article (PubMed ID: 8519488)
21. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
[TBL] [Abstract][Full Text] [Related]
22. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
23. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
[TBL] [Abstract][Full Text] [Related]
24. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
25. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
26. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
29. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
[TBL] [Abstract][Full Text] [Related]
30. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
Berdel WE; Kulimova E; Kolkmeyer A; Zühlsdorf M; Serve H; Büchner T; Oelmann E
Ann Hematol; 2005 Nov; 84(12):771-3. PubMed ID: 16094532
[TBL] [Abstract][Full Text] [Related]
31. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
32. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
33. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Reuning U; Magdolen V; Hapke S; Schmitt M
Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
35. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
37. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
38. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
[TBL] [Abstract][Full Text] [Related]
39. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract][Full Text] [Related]
40. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]